Patients in the trial
VF, pigmentary glaucomas, glaucomatous, visual field damage, stroke, pseudoexfoliative, dementia, Parkinson’s disease, Glaucoma, OAG, glaucoma, glaucomatous damage, VF damage
PIGMENTARY GLAUCOMA, STROKE, OPTIC NERVE, GLAUCOMA, GLAUCOMA
Glaucoma definition was based on VF damage (24–2 SITA standard strategy, Humphrey Visual Field Analyser, HFA) corresponding to glaucomatous changes at the optic nerve head (ONH) irrespective of IOP. Inclusion criteria were patients with OAG, including pseudoexfoliative and pigmentary glaucomas; age ≥ 18 years; presence of bilateral visual field damage; a level of moderate damage in the better eye, with a mean deviation (MD) ranging from − 5 to − 13 dB at the screening assessment; controlled IOP (according to physician’s judgement); and a signed consent form to participate in the study. Exclusion criteria were single-eyed patients; patients without those psychophysical requirements to adequately participate and complete the trial; patients with other types of glaucoma; patients with other ocular comorbidities interfering with the correct assessment of the glaucomatous damage to the VF; patients who had undergone surgery within 6 months; patients taking other potential neuroprotectors; patients with Parkinson’s disease, dementia or a diagnosis of stroke in the last 6 months.